logo
AHCS | Information Portal<p>The AHCS Information Portal is your one stop information area consisting of the Information Station & Health Hub.</p>AHCS | Support Forums

Fatigue In HCV Infection: A Review (1989 - 2011)


Take me to the review! >>>

world_hepc_news_logo

Tue

21

May

2013

What About Us? - Pakistan & Hepatitis C

Directly acting antiviral (DAA) agents are currently revolutionizing the treatment of chronic hepatitis C infection. The first generation of these agents have significant limitations including cost issues that are of particular concern in the developing world and a lack of efficacy in genotype 3 patients. Both of these concerns are of particular relevance in Pakistan.

One cannot attend any major international liver conference over the past 1 year and not be struck by the vast array of new directly acting antiviral (DAA) agents currently in the pipeline. Telaprevir and boceprevir have already been licensed for use in Western countries. Although these and other agents will revolutionize the treatment of chronic hepatitis C, these advances threaten to leave some parts of the world, the developing world in particular, and a large proportion of the world's hepatitis C burden, behind.

 

Thu

16

May

2013

Baby Boomer Resource Feedback

Baby boomer resource feedback

Hepatitis Queensland has produced a poster to be used during the 2013 World Hepatitis Day campaign. The primary aim of this resource is to engage the baby boomer generation with healthcare services and management of their hepatitis C.  We are currently collecting comments on this draft.  If you can help us with providing feedback that would be appreciated. Go to https://www.surveymonkey.com/s/BabyBoomerWHD13  and submit your comments before 5:00PM Wednesday 22 May 2013.

 

Thu

16

May

2013

Hep Survey & Win iPad Mini

There are several promising new hepatitis C treatments in development, including the first all oral medications, which may be of use to you, your family and friends affected by hepatitis C.

Our team tries to find new answers that could help you and the rest of our online community – this is why we’re asking you the following questions.

The survey will only take around 5 minutes of your time, your responses will remain confidential and anonymous and, at the end of the survey, you’ll be able to enter a prize draw for a chance to win an iPad mini.

We would greatly appreciate if you could complete the survey and, if appropriate, share with friends and on your site.

The winner will be selected at random and notified by email by 24 May 2013.

Survey is here: https://www.surveymonkey.com/s/5HD7SKN

 

Sun

28

Apr

2013

Oral Regimen Sustains Hepatitis C Viral Response to 24 Weeks

AMSTERDAM, the Netherlands — A regimen of 3 direct-acting antiviral drugs plus ritonavir and ribavirin produced sustained virologic response rates in more than 90% of a broad range of patients infected with hepatitis C 24 weeks after therapy, results from a new clinical trial show.

Kris Kowdley, MD, from the Liver Center of Excellence in the Digestive Disease Institute at Virginia Mason Medical Center in Seattle, Washington, presented the results here at the International Liver Congress 2013.

The randomized, open-label, multicenter phase 2b trial, known as Aviator, shows that the sustained virologic responses seen at 12 weeks with an all-oral interferon-free regimen, presented last year at the annual meeting of the American Association for the Study of the Liver Diseases by Dr. Kowdley, are sustainable.

In the Aviator trial, noncirrhotic patients with genotype 1 hepatitis C virus who were treatment-naïve or had not responded to peginterferon and ribavirin were treated with combinations of direct-acting antiviral drugs with or without ribavirin for 8, 12, or 24 weeks.

The direct-acting antiviral drugs were once-daily ABT-450r (an NS3/4A protease inhibitor boosted with ritonavir), once-daily ABT-267 (an NS5A inhibitor), and twice-daily ABT-333 (a non-nucleoside NS5B inhibitor).

The 571 patients were predominantly white, and the mean age was 48 to 53 years. The majority, 59% to 71%, had hepatitis C genotype 1a, and mean baseline viral load was 6.6 log10 hepatitis C RNA. Overall, 27% to 34% of treatment-naive patients had genotype IL28B CC, whereas only 2% to 4% of the null responders did.

Patients coinfected with HIV or hepatitis B were excluded from the study.

For the 79 treatment-naive patients who received the regimen consisting of 3 direct-acting antiviral drugs plus ribavirin for 12 weeks, 96% achieved sustained virologic response rates at 24 weeks (99% achieved this at 12 weeks).

 

Thu

25

Apr

2013

Police officer who got Hepatitis C in brawl with suspect wins compensation battle

A POLICE officer who contracted Hepatitis C in a brawl with a drunken suspect has won his nine-year battle for worker's compensation.

In a judgment published today, the Workers Compensation Tribunal has found SA Police must pay for the officer's physical and psychological suffering.

Deputy President Judge Peter McCusker ruled medical evidence proved the officer, known as "P", contracted the virus while on duty in 1988.

"I find the worker suffered injury in the nature of Hepatitis C and subsequent fatigue, irritable bowel syndrome and psychological disability... in the course of employment," he said.

"The worker has been thereby incapacitated."

In his judgment, Judge McCusker said P's illness arose from an incident on October 17, 1988.

At the time, P was stationed at Darlington, and had pulled a driver over on Ocean Boulevard for a drink-driving check.

"(The driver) was instructed to remain at the scene (but) disobeyed this direction," he said.

"(The driver) hit P violently with a closed fist, breaking his nose and causing a significant facial cut that bled.

"P ultimately required two stitches (because) blood was flowing freely from his nose."

Judge McCusker said the driver - "a muscular" 25-year-old with prominent tattoos - also bashed his own head on the car's door frame.

"P's partner recorded the driver's face being flushed and `covered in blood'," he said.

Subsequent testing revealed the driver was an intravenous drug user who carried the Hepatitis C virus.

In 2004, P was unable to continue working due to treatment for the virus.

Citing extensive medical evidence, Judge McCusker said the 1988 incident was the only possible source for P's Hepatitis C.

He said the officer had never used intravenous drugs, had unsafe sex or had a "hairdressing cut".

"P's main problem is his fatigue and this clearly incapacitates him," he said.

"He is no longer fit for patrol work."

He upheld P's claim and ordered the parties to present submissions on the amount and form of compensation to be provided.

http://www.adelaidenow.com.au

 
AHCS | Join Our Community!

Latest Forum Topics

Online Users

0 users and 38 guests online